GlassScriptPhysician profile
Veronica Benedit
NPI 1396414033
$802.30
in general payments reported to CMS, 2019-2025
14 companies · $535 in 2025
The $535 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $13.32 · 2023: $34.16 · 2024: $219 · 2025: $535.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $789.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $788.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $160.82 | 2024-2025 | Verquvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $134.97 | 2024-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $88.50 | 2024-2025 | Camzyos |
| Boston Scientific Corporation | $76.50 | 2024-2025 | Bodyguardian, Watchman Access System, Ekosonic |
| Novo Nordisk INC | $72.45 | 2025 | Wegovy, Ozempic |
| Amgen INC. | $70.14 | 2024-2025 | Repatha, Repatha |
| Scpharmaceuticals INC. | $35.26 | 2025 | |
| United Therapeutics Corporation | $34.16 | 2023 | Tyvaso |
| Bayer Healthcare Pharmaceuticals INC. | $28.25 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $25.00 | 2025 | Opsynvi |
| Mylan Specialty L.P. | $25.00 | 2024 | Yupelri |
| Philips North America LLC | $20.99 | 2025 | Extended Holter |
| Astrazeneca Pharmaceuticals LP | $16.94 | 2024 | Farxiga |
| Resmed Corp | $13.32 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Veronica Benedit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.